Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Chief Financial Officer | February 16, 2023 | February 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date February 16, 2023 · Filed February 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 313,497 |
Reported balance
After 2023-02-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-16 · Sale · Disposed 10,267 · Balance 313,497 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
F3: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 18, 2023 01:58 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,267 | $3.00 | $30,801.00 |
DisclosureSEC source: 0001209191-23-010953 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,497 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,095 | $3.57 | $39,609.15 |
DisclosureSEC source: 0001209191-22-057966 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,764 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.42 to $3.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,006 | $4.76 | $9,548.56 |
DisclosureSEC source: 0001209191-22-046487 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,859 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock · Derivative | 331,875 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-22-046487 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,875 Underlying: Common Stock · 331,875 shares Expires 2030-08-14 F5 · security: Stock options were granted in connection with a retention program and the individual's recent promotion. These stock options are in lieu of the Issuer's usual end-of-year annual performance grants. F6 · derivative.exercise_date: Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 165,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046487 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,865 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and the individual's recent promotion. This grant is in lieu of Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,841 | $3.95 | $23,071.95 |
DisclosureSEC source: 0001209191-22-029903 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,427 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2022 Filed May 18, 2022 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029903 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,268 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:18 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,363 | $10.95 | $25,874.85 |
DisclosureSEC source: 0001209191-22-011439 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,318 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:26 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 37,600 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070693 · doc4.xml · derivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,600 Underlying: Common Stock · 37,600 shares Expires 2029-12-15 F3 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:26 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 21,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070693 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,681 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,741 | $13.16 | $88,711.56 |
DisclosureSEC source: 0001209191-21-065223 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,981 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 14,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065223 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,722 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 01:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 26,600 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060511 · doc4.xml · derivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires 2027-12-11 F1 · security: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · derivative.exercise_date: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019). Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,339 | $13.83 | $184,478.37 |
DisclosureSEC source: 0001209191-21-052390 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,822 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,391 | $18.30 | $245,055.30 |
DisclosureSEC source: 0001209191-21-034188 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,161 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,705 | $22.37 | $261,840.85 |
DisclosureSEC source: 0001209191-21-012122 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,552 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 37,500 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-006211 · doc4.xml · derivative · entry 5 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 37,500 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-006211 · doc4.xml · derivative · entry 4 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 75,000 | $18.62 | $1,396,500.00 |
DisclosureSEC source: 0001209191-21-006211 · doc4.xml · nonDerivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,257 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $18.26 to $19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 37,500 | $8.80 | $330,000.00 |
DisclosureSEC source: 0001209191-21-006211 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 37,500 | $8.80 | $330,000.00 |
DisclosureSEC source: 0001209191-21-006211 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:51 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 28,600 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064916 · doc4.xml · derivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,600 Underlying: Common Stock · 28,600 shares Expires 2028-12-17 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:51 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064916 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,257 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,976 | $16.93 | $202,753.68 |
DisclosureSEC source: 0001209191-20-059243 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,757 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.71 to $17.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,367 | $19.67 | $26,888.89 |
DisclosureSEC source: 0001209191-20-047617 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,733 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,190 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,367 | $22.51 | $30,771.17 |
DisclosureSEC source: 0001209191-20-031016 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,719 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.29 to $22.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,809 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,394 | $22.35 | $31,155.90 |
DisclosureSEC source: 0001209191-20-011262 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,086 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,809 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 37,500 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-20-007713 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2020. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 37,500 | $22.78 | $854,250.00 |
DisclosureSEC source: 0001209191-20-007713 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,480 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.55 to $23.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,809 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 37,500 | $7.21 | $270,375.00 |
DisclosureSEC source: 0001209191-20-007713 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2020. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,809 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 11,800 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060789 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires 2027-12-11 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 26,600 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060789 · doc4.xml · derivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires 2027-12-11 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 14,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060789 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,480 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,809 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,713 | $17.97 | $48,752.61 |
DisclosureSEC source: 0001209191-19-057491 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,441 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.56 to $19.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,670 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,809 | $18.15 | $32,833.35 |
DisclosureSEC source: 0001209191-19-046722 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,154 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,670 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2019 Filed May 18, 2019 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,928 | $31.37 | $60,481.36 |
DisclosureSEC source: 0001209191-19-031190 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,463 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.86 to $32.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,808 | $42.39 | $76,641.12 |
DisclosureSEC source: 0001209191-19-012337 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,391 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 16,119 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-19-007880 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,119 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2019. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 16,119 | $42.16 | $679,577.04 |
DisclosureSEC source: 0001209191-19-007880 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,199 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.15 to $42.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 16,119 | $10.69 | $172,312.11 |
DisclosureSEC source: 0001209191-19-007880 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 7, 2019. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,150 | $0.00 Strike: $36.51 | $0.00 |
DisclosureSEC source: 0001209191-18-063302 · doc4.xml · derivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,150 Underlying: Common Stock · 22,150 shares Expires 2026-12-13 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063302 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,199 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,016 | $38.25 | $153,612.00 |
DisclosureSEC source: 0001209191-18-059297 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,249 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 23:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057268 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,265 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest quarterly in substantially equal installments on November 15, 2020, February 15, 2021, May 15, 2021, and August 15, 2021, based on the reporting person's continued service with the Company. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:47 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 4,883 | $58.40 | $285,167.20 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,265 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:47 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 26,250 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-12-14 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F6 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:47 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,148 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2018 Filed May 18, 2018 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,576 | $83.39 | $298,202.64 |
DisclosureSEC source: 0001209191-18-031598 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,281 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.35 to $84.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,703 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 13,881 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-025445 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,119 Underlying: Common Stock · 13,881 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 22:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,881 | $101.46 | $1,408,366.26 |
DisclosureSEC source: 0001209191-18-025445 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,857 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $100.21 to $101.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 3,703 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.